Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

基因编辑技术近年来迅速发展，尤其是著名的CRISPR/Cas9工具，使我们在医学与农业等领域的应用前景广阔。CRISPR，源自细菌，为抵御病毒而演化出的防御机制，现被应用于精确修改DNA，宛如科学界的"基因魔剪"。

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...